A blood proteome panel distinguishes Alzheimer's, Lewy body and frontotemporal dementia — Nature Aging (20 Jul 2026)

Why it matters (spine). Blood biomarkers for Alzheimer's have advanced quickly, but they mostly answer "is this Alzheimer's or not?" The harder, more clinically useful question is which dementia — because Alzheimer's, dementia with Lewy bodies, and frontotemporal dementia need different management, and mixing them contaminates clinical trials. A plasma panel that separates the three from a blood draw is a step toward precision neurology at population scale: cheaper, less invasive than PET or CSF, and deployable in primary care. Money angle: a validated, multiplexed blood panel is a scalable diagnostic product and a trial-enrichment tool. Metacrisis lever: dementia is one of the largest and fastest-growing global disease burdens; accurate, accessible differential diagnosis is a genuine public-health instrument.

What would prove it wrong (falsifier). If independent groups cannot replicate the subtype separation in new cohorts, or the 21-protein panel fails to hold up prospectively (in real, unselected clinical populations rather than well-characterized research cohorts), the "differential diagnosis from blood" claim weakens from a validated research finding to a promising-but-unconfirmed one. The card verifies the study result, not a clinical-grade, regulator-cleared test.

Live-status check + triangulation. Quoted from the paper's abstract (Nature Aging, published 20 July 2026; DOI 10.1038/s43587-026-01162-7; fetched and read in-session): "We analyzed 1,318 plasma samples from well-characterized international cohorts and identified more than 200 dysregulated proteins across disease groups… We translated these findings into a 21-protein quantitative multiplex panel and validated it in an independent multicenter cohort (n = 805). These findings support plasma proteomics as an approach for biomarker-based differential diagnosis and disease staging across major neurodegenerative dementias." Signature markers named in the abstract: GFAP rises along the AD continuum; integrin alpha-V and alpha-M are reduced in Lewy body disorders (including autopsy-confirmed cases); elevated neurofilament light with lower GFAP tracks FTD. Lead/senior authors include Giovanni Bellomo, Lisa Vermunt and Marta del Campo. Independently echoed by trade coverage (Inside Precision Medicine) treated only as a lead.

Honest scope (what is NOT verified here). Verified: the peer-reviewed finding — sample counts, the >200-protein signal, the 21-protein panel and its independent validation (n = 805), and the marker directions — as stated in the primary. NOT verified and deliberately not claimed: that this is an available, approved, or clinically deployed test; that it performs equally in unselected primary-care populations; or any specific per-subtype accuracy figure beyond what the abstract states. This is a research result with a validated assay, not a cleared diagnostic.